A concurrent advancement in prostate cancer care that may have impacted on evolving management of cN1M0PC is the advent of novel imaging such as prostate‐specific membrane antigen positron emission tomography (PSMA‐PET). This evidence concerns the gene FOLH1 and Familial prostate cancer.